Posts

Kura Reports Durable Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve ccRCC at KCRS 2026

on

GSK readies global submissions for Jemperli in dMMR/MSI-H rectal cancer

on

Eisai, Biogen scoop up subQ Leqembi starter‑dose nod – FDA greenlights subcutaneous lecanemab initiation for early Alzheimer’s disease

on

UK launches national dementia registry to speed up search for treatments

on

Recent News About Tris Pharma's Narcolepsy Drug and Agenus' Phase 3 CRC Trial Abandonment

on

Recent News: ARPA-H Awards Up to $160M for Custom Genetic Medicines

on

Vera’s IgAN Approval Kicks Off Competition with Otsuka

on

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

on

Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

on

RQ Bio raises $115M to advance long‑acting flu prevention antibody into clinic

on

Federal health agencies unveil plan to speed up Phase 1 clinical trials by 6 to 12 months

on

Trace Neuroscience launches first global clinical program for TRCN‑1023 ASO in ALS

on

Converting nonresponder insights into smarter drug development strategies in immunology

on

Novo Nordisk hit by multi‑million‑dollar ransom demands after major data breach claimed by hacking groups

on

Takeda's AI‑designed psoriasis pill beats Bristol Myers Squibb's Sotyktu in Phase 3 head‑to‑head trial

on

ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program

on

Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027

on